Brief: Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy For Treatment Of B-Cell Non-Hodgkin Lymphomas
01/11/2021 13:49
Nov 1 (Reuters) - Mustang Bio Inc MBIO.O :
* MUSTANG BIO AWARDED NIH GRANT FOR MB-106 CD20-TARGETED CAR
T
CELL THERAPY FOR TREATMENT OF B-CELL NON-HODGKIN LYMPHOMAS
Source text for Eikon: ID:nGNX7mRtc1
Further company coverage: MBIO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie